Recent studies suggest that sodium tanshinone IIA sulfonate (STS) may offer therapeutic benefits in managing essential hypertension (EH). This study systematically evaluates the efficacy and safety of STS in EH treatment.
Materials and methods
A comprehensive search was conducted across seven databases: PubMed, Cochrane Library, Embase, Wanfang, China Biomedical Literature Service System, VIP Chinese Sci-tech Journal Database, and China National Knowledge Infrastructure from their inception through February 4, 2025. Methodological quality was evaluated using Cochrane Handbook guidelines. Meta-analysis was performed using Stata 14.0.
Results
Twenty-two studies involving 2347 patients were included. Combining STS with conventional therapy significantly reduced systolic blood pressure (WMD: −8.37, 95% CI: −10.28 to −6.45), diastolic blood pressure (WMD: −5.68, 95% CI: −6.67 to −4.68), serum creatinine (WMD: −16.89, 95% CI: −21.37 to −12.41), total cholesterol (WMD: −2.45, 95% CI: −2.58 to −2.32), and endothelin-1 (WMD: −9.13, 95% CI: −13.64 to −4.63). Nitric oxide significantly increased (WMD: 8.98, 95% CI: 6.38 to 11.58).
Conclusions
The combination of STS with conventional therapy demonstrates significant improvements in blood pressure, vascular endothelial function, and renal function. STS may serve as an adjunctive treatment for EH.
TouyzRM. Hypertension guidelines: effect of blood pressure targets. Can J Cardiol2019; 35: 564–569.
2.
TeixeiraMBarrosoWBrandãoA, et al.Spirituality-based intervention in hypertension: eFfects on blood PrEssure and EndotheliaL function-FEEL trial results. Glob Heart2025; 20: 6.
3.
AhmadHKhanHHaqueS, et al.Angiotensin-Converting enzyme and hypertension: a systemic analysis of various ACE inhibitors, their side effects, and bioactive peptides as a putative therapy for hypertension. J Renin Angiotensin Aldosterone Syst2023; 2023: 7890188.
4.
DongHZhangSDuW, et al.Pharmacodynamics and metabonomics study of Tianma Gouteng Decoction for treatment of spontaneously hypertensive rats with liver-yang hyperactivity syndrome. J Ethnopharmacol2020; 253: 112661.
5.
TianHAnLWangP, et al.Review of Astragalus membranaceus polysaccharides: extraction process, structural features, bioactivities and applications. Chin Herb Med2024; 17: 56–69.
6.
LiuTHChenWHChenXD, et al.Network pharmacology identifies the mechanisms of action of TaohongSiwu decoction against essential hypertension. Med Sci Monit2020; 26: e920682.
7.
TaiJZouJZhangX, et al.Randomized controlled trials of tianma gouteng decoction combined with nifedipine in the treatment of primary hypertension: a systematic review and meta-analysis. Evid Based Complement Alternat Med2020; 2020: 5759083.
8.
QianLYanSLiY, et al.The effects of gastrodin injection on hypertension: a systematic review and meta-analysis. Medicine (Baltimore)2020; 99: e20936.
9.
LiLZhongSYeJ, et al.Shenmai injection revives cardiac function in rats with hypertensive heart failure: involvement of microbial-host co-metabolism. BMC Complement Med Ther2025; 25: 24.
10.
JiaELiHHeF, et al.Metabolic engineering of artificially modified transcription factor SmMYB36-VP16 for high-level production of tanshinones and phenolic acids. Metab Eng2024; 86: 29–40.
11.
SudhaSUpmanyuASaraswatD,et al.Pharmacological impacts of tanshinone on osteogenesis and osteoclastogenesis: a review. Naunyn Schmiedebergs Arch Pharmacol2025; 398: 135–146.
12.
WuRZhouYXuH, et al.Aqueous extract of Salvia miltiorrhiza Bunge reduces blood pressure through inhibiting oxidative stress, inflammation and fibrosis of adventitia in primary hypertension. Front Pharmacol2023; 14: 1093669.
13.
CaoYZhaoHLinS, et al.Danshen injection ameliorates unilateral ureteral obstruction-induced renal fibrosis by inhibiting ferroptosis via activating SIRT1/GPX4 pathway. Front Pharmacol2025; 15: 1503628.
14.
KumarRMalikSTiwariR, et al.Pathophysiology of cardiovascular diseases and the role of vitamins, and herbal extracts in the reduction of cardiovascular risks. Cardiovasc Hematol Agents Med Chem2021; 19: 175–186.
15.
GuoRLiLSuJ, et al.Pharmacological activity and mechanism of tanshinone IIA in related diseases. Drug Des Devel Ther2020; 14: 4735–4748.
16.
ChenZPengYYangF, et al.Traditional Chinese medicine injections combined with antihypertensive drugs for hypertensive nephropathy: a network meta-analysis. Front Pharmacol2021; 12: 740821.
17.
XuJZhangCShiX, et al.Efficacy and safety of Sodium Tanshinone IIA Sulfonate Injection on hypertensive nephropathy: a systematic review and meta-analysis. Front Pharmacol2019; 10: 1542.
18.
BiXJWangLNXinHJ, et al.The therapeutic effect of Sodium Tanshinone IIA Sulfonate Injection combined with irbesartan in the treatment of hypertension with renal injury and its impact on serum PCX and PICP levels. Northw Pharm J2016; 31: 403–405(In Chinese).
19.
CaoGQXuXHHanRQ. Analysis of the therapeutic effect of irbesartan combined with Sodium Tanshinone IIA Sulfonate Injection in the treatment of hypertension with renal damage. J Ration Clin Use2014; 7: 46–47(In Chinese).
20.
GaoAHLiJPZhuCX, et al.The effect of Sodium Tanshinone IIA Sulfonate Injection combined with nifedipine on patients with primary hypertension. J Pract Cardiovasc Cerebrovasc Diseases2018; 26: 133–135(In Chinese).
21.
JiaHLiuQ. The effect of Sodium Tanshinone IIA Sulfonate Injection combined with diltiazem on endothelial function in hypertensive patients. J Cardiovasc Rehabil Med2017; 26: 490–492(In Chinese).
22.
LiJ. The efficacy of losartan combined with Sodium Tanshinone IIA Sulfonate Injection in the treatment of hypertensive kidney damage. Med Inform2019; 32: 138–140(In Chinese).
23.
LiQHGuoJ. The effect of Sodium Tanshinone IIA Sulfonate Injection combined with valsartan on hypertensive kidney damage patients. Xinjiang Med J2017; 47: 1304–1305+1308(In Chinese).
24.
LiuFZ. Clinical characteristics of hypertensive nephropathy and evaluation of the therapeutic effect of Sodium Tanshinone IIA Sulfonate Injection combined with valsartan. Electron J Integr Trad Chin Western Med Cardiovasc Disease2018; 6: 74(In Chinese).
25.
LiYJ. Clinical observation on the treatment of 115 cases of hypertensive renal damage with Sodium Tanshinone IIA Sulfonate Injection combined with valsartan. Chinese Ethnic Folk Med2014; 23: 57–58(In Chinese).
26.
LuoWW. Observation of the therapeutic effect of valsartan combined with Sodium Tanshinone IIA Sulfonate Injection in the treatment of hypertensive nephropathy. Northern Pharm2015; 12: 37–38(In Chinese).
27.
LvZG. The effect of Sodium Tanshinone IIA Sulfonate Injection combined with valsartan on oxidative stress response in patients with hypertensive nephropathy. Clin Med2018; 38: 108–109(In Chinese).
28.
MuS. Clinical efficacy observation of valsartan combined with Sodium Tanshinone IIA Sulfonate Injection in the treatment of 64 cases of hypertensive kidney damage. Chin Med Guidelines2017; 15: 3+5(In Chinese).
29.
ShangXB. The effect of irbesartan and Sodium Tanshinone IIA Sulfonate Injection combination on related indexes of hypertension patients with diabetic nephropathy. Chin J Modern Med2019; 21: 54–58(In Chinese).
30.
ShiHBLiYFXuJH, et al.The therapeutic effect of Sodium Tanshinone IIA Sulfonate Injection combined with irbesartan on urinary NAG, β2-MG, PICP and PCX levels. Res Pract Healthc Med2020; 17: 45–49(In Chinese).
31.
YangDWHeHZLiangLP. Clinical observation of Sodium Tanshinone IIA Sulfonate Injection combined with enalapril in the treatment of elderly primary hypertension. Prev Treat Cardiovasc Cerebrovasc Diseases2019; 19: 438–439(In Chinese).
32.
YangHYZhanHPChenH. Observation of the therapeutic effect of the combination therapy of Sodium Tanshinone IIA Sulfonate Injection and valsartan on hypertensive nephropathy. J Pract Med2012; 28: 340–341(In Chinese).
33.
YangWCHuangFXiYB, et al.The effect of Sodium Tanshinone IIA Sulfonate Injection combined with Captopril on primary hypertension and endothelial function. Chin J Clin Phys2018; 46: 785–786(In Chinese).
34.
ZangBY. Clinical observation of Sodium Tanshinone IIA Sulfonate Injection combined with captopril tablets in the treatment of primary hypertension. Hebei Trad Chin Med2018; 40: 1845–1849(In Chinese).
35.
ZhangSQ. The clinical efficacy of Sodium Tanshinone IIA Sulfonate Injection combined with Captopril in the treatment of hypertension complicated with heart failure and the influence of serum hs CRP and BNP levels. Contemp Med2020; 26: 178–180(In Chinese).
36.
ZhuHWZhuMGaoJD. Clinical study on the treatment of hypertensive nephropathy with Sodium Tanshinone IIA Sulfonate Injection. Internal Med Theory Pract2011; 6: 204–207(In Chinese).
37.
ZhuJ. Observation of the therapeutic effect of Sodium Tanshinone IIA Sulfonate Injection combined with benazepril in the treatment of primary hypertension. Modern Drugs Clin Pract2015; 30: 409–412(In Chinese).
38.
ZhuXLLuLMZhuJP, et al.The effect of Sodium Tanshinone IIA Sulfonate Injection on blood lipid levels and endothelial function in patients with primary hypertension. Adv Modern Biomed Sci2016; 16: 3932–3935(In Chinese).
39.
ZouHLZhanJWangYJ,et al.Sodium Tanshinone IIA Sulfonate Injection combined with valsartan for the treatment of hypertensive nephropathy. J Integr Trad Chin Western Med Cardiovasc Cerebrovasc Diseases2013; 11: 1303–1304(In Chinese).
40.
WangLSongTDongC,et al.Association between interactions among ACE gene polymorphisms and essential hypertension in patients in the Hefei Region, Anhui, China. J Renin Angiotensin Aldosterone Syst2023; no: 1159973.
41.
LaiXFangZDongZ, et al.A propensity score matched comparison of blood pressure lowering in essential hypertension patients treated with antihypertensive Chinese herbal Medicine: comparing the real-world registry data vs. randomized controlled trial. Clin Exp Hypertens2023; 45: 2249269.
42.
NagibSNAbdelwahabSAminGEE,et al.What is the prevalence of chronic kidney disease among hypertensive non-diabetic Egyptian patients attending primary healthcare?Clin Exp Hypertens2023; 45: 2203411.
